Glaxosmithkline Biologicals Sa

Hookipa Biotech Gmbh

Anders Lilja

Peter W Mason

Thomas P Monath

Michael Schwendinger

Michael Franti

Katherine Cohen

Sarah Schmidt

Klaus Orlinger

Gerhard Fuhrmann

Andreas Aspöck

Elizabeth Watson

Bettina Kiefmann

Julia Hinteramskogler

Ursula Berka

Rebecca Loomis

Andrea Carfi

Yingxia Wen

Holger Laux

Claudio Ciferri

Irmgard Hofmann

The invention relates to platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using such platforms permits the generation of broad and potent immune responses useful for vaccine development.

Antigen delivery platforms

Provided herein are genetically modified arenaviruses suitable as vaccines against neoplastic diseases or cancer. The invention also relates to pharmaceutical compositions and methods for the prevention or treatment of certain infections causing neoplastic diseases or cancer, such as infections with oncogenic viruses. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing or treating diseases and conditions caused by and associated with infections with Human Papillomavirus (HPV), such as cervical cancer, anogenital cancer, head and neck cancer and skin cancers. Also provided herein are immunotherapies for the treatment of a neoplastic disease, such as a neoplastic disease caused by infection with oncogenic viruses.

HPV vaccines

This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.

Mammalian cells expressing cytomegalovirus antigens

Growing community of inventors

Vienna, Austria

Anders Lilja